News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GTx, Inc. (GTXI) Provides Corporate Update And Reports 2013 Financial Results


3/4/2014 8:08:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the fourth quarter and full year 2013.

Clinical updates

Enobosarm (GTx-024) 3 mg, an oral selective androgen receptor modulator, being developed for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer: GTx announced in August 2013 that the POWER1 (platinum plus taxane) and POWER2 (platinum plus non-taxane) Phase 3 clinical trials evaluating enobosarm 3 mg for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer (NSCLC) failed to meet the co-primary endpoints of lean body mass and physical function that were assessed statistically using responder analyses, as agreed upon with the Food and Drug Administration (FDA).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
GTx, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES